• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 27, 2013

View Archived Issues

Esperion Prices Upsized $70M IPO for Statin Alternative Work

Following in the footsteps of upsized initial public offerings (IPOs) from PTC Therapeutics Inc. and Bluebird Bio, Plymouth, Mich.-based Esperion Therapeutics Inc. priced an IPO to raise $70 million – $80.5 million if underwriters exercise overallotments in full – to support midstage testing of its lead compound, ETC-1002, as an alternative to statin therapy in lowering LDL-cholesterol (LDL-C). Read More

Reverse Vaccine Strikes Blow Against Type I Diabetes

Tolerion Inc. reported Phase II results showing promising disease-modifying activity of its lead product TOL-3021 against Type I diabetes. Read More

Heptares $21M Series B Paves Way for Phase I in CNS Disorders

LONDON – Heptares Ltd. has raised $21 million in a Series B funding co-led by the Stanley Family Foundation, one of the leading foundations investing in neuroscience diseases. Read More

SEC Seeks More Funding to Tackle Plateful of Rulemaking

When SEC Chairwoman Mary Jo White testified before a Senate Appropriations subcommittee this week, it wasn't to make excuses for missed deadlines under the Jumpstart Our Business Startups (JOBS) Act or promise when those long overdue rules would be released. Read More

Complix Gets $16M for Its Alphabody Scaffold Technology

Complix NV raised €12 million (US$15.6 million) in a Series B round to fund development of small-protein therapeutics based on its alphabody scaffold platform. Read More

Stock Movers

Read More

Other News To Note

• Chimerix Inc., of Durham, N.C., said it will be included in the Russell 2000, Russell 3000 and Russell Global Indexes at the close of market on June 28. Read More

Pharma: Other News To Note

• Roche AG, of Basel, Switzerland, and Astrazeneca plc, of London, have allied to share research data related to drug design. Read More

Clinic Roundup

• Labrys Biologics Inc., of San Mateo, Calif., disclosed data from three late-breaking poster presentations demonstrating the pharmacokinetics and safety profile of LBR-101 (formerly RN-307) observed in multiple Phase I trials. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 2, 2025.
  • AI-generated illustration of CAR T cells

    Researchers arm CAR T cells to fight solid tumors

    BioWorld
    Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...
  • Digital lungs illustration

    Bioversys, Shionogi in CHF529M lung infection collaboration

    BioWorld Science
    Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on...
  • Medtronic Vitalflow ECMO

    Medtronic receives CE mark for its Vitalflow ECMO system

    BioWorld MedTech
    Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe